Filing Flows › Comparisons › BFRI vs LXRX
Biofrontera vs Lexicon Pharmaceuticals: BFRI and LXRX compared
Biofrontera is the larger company: $12.0M of revenue in its latest quarter (Q2 2026) against $11.2M for Lexicon Pharmaceuticals (Q3 2026). Biofrontera is growing faster (+33% against -21% a year earlier). Biofrontera is more profitable, with an operating margin of -4.4% against -128.8%.
Where the money goes: BFRI and LXRX
Biofrontera (BFRI) · Q2 2026
Biofrontera, Q2 2026: revenue $12.0M (+33% year over year), operating margin -4.4%, net loss $604K, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
Lexicon Pharmaceuticals (LXRX) · Q3 2026
Lexicon Pharmaceuticals, Q3 2026: revenue $11.2M (-21% year over year), operating margin -128.8%, net loss $14.0M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Biofrontera (BFRI) | Lexicon Pharmaceuticals (LXRX) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $12.0M | $11.2M |
| Revenue growth, Y/Y | +33% | -21% |
| Operating margin | -4.4% | -128.8% |
| Net earnings | −$604K | −$14.0M |
| Net margin | -5.0% | -124.5% |
| Operating cash flow | −$1.7M | −$8.1M |
Questions
Which is bigger, Biofrontera or Lexicon Pharmaceuticals?
Biofrontera is the larger company: $12.0M of revenue in its latest quarter (Q2 2026) against $11.2M for Lexicon Pharmaceuticals (Q3 2026).
Is Biofrontera or Lexicon Pharmaceuticals growing faster?
Biofrontera is growing faster (+33% against -21% a year earlier).
Which is more profitable, Biofrontera or Lexicon Pharmaceuticals?
Biofrontera is more profitable, with an operating margin of -4.4% against -128.8%.
More: Biofrontera earnings · how Biofrontera makes money · Lexicon Pharmaceuticals earnings · how Lexicon Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.